Compounds and methods for regulating integrins
View Patent ↗A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a β2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a β2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a β2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating β2 integrins.
1. A method for treating breast cancer, the method comprising:
administering to a patient in need thereof a β2 integrin agonist having the formula
or a pharmaceutically acceptable salt thereof, wherein:
A is absent or is selected from alkyl and alkenyl,
B is absent or is selected from alkyl, alkenyl, O, S, and NR 4 ,
X is selected from O and S,
R 1 is selected from alkoxycarbonyl, aryl, heteroaryl, carbocyclyl, and heterocyclyl,
R 2 is H,
R 3 is phenyl which is unsubstituted or substituted with one or two substituents independently selected from halogen, nitro, cyano, hydroxyl, thiol, amino, alkoxy, alkylamino, alkylthio, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, alkyl, and carboxy, and
R 4 is selected from hydrogen and alkyl; and
reducing tumor growth.
2. The method of claim 1 , further comprising administering radiation or an anti-cancer compound to the patient.
3. The method of claim 2 , comprising administering the anti-cancer compound which is paclitaxel.
4. The method of claim 1 , wherein the breast cancer is metastatic breast cancer.
5. The method of claim 1 , wherein reducing tumor growth includes reducing the number of inflammatory leukocytes recruited to the tumor.
6. The method of claim 1 , wherein the β2 integrin agonist is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
7. The method of claim 6 , wherein the β2 integrin agonist is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
8. The method of claim 1 , wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.